These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 10064007)

  • 1. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
    Xiao Z; Théroux P; Frojmovic M
    Thromb Haemost; 1999 Feb; 81(2):281-5. PubMed ID: 10064007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
    Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
    Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of fibrinogen binding and surface recruitment of GpIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852.
    Wittig K; Rothe G; Schmitz G
    Thromb Haemost; 1998 Mar; 79(3):625-30. PubMed ID: 9531053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
    Barlage S; Wimmer A; Pfeiffer A; Rothe G; Schmitz G
    Platelets; 2002 May; 13(3):133-40. PubMed ID: 12180495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients.
    Keularts IM; Béguin S; de Zwaan C; Hemker HC
    Thromb Haemost; 1998 Sep; 80(3):370-1. PubMed ID: 9759611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
    Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
    Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
    Hézard N; Metz D; Garnotel R; Droullé C; Potron G; Nguyen P
    J Mal Vasc; 2000 Dec; 25(5):343-348. PubMed ID: 11148396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
    Faraday N; Braunstein JB; Heldman AW; Bolton ED; Chiles KA; Gerstenblith G; Schulman SP
    Platelets; 2004 Feb; 15(1):9-14. PubMed ID: 14985171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
    Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
    Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
    Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
    Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
    Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
    Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
    Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein specifically binds glycoprotein IIb/IIIa: a flow cytometric method for ligand-receptor interaction.
    Tetik S; Uras F; Ekşioğlu-Demiralp E; Turay Yardimci K
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):210-9. PubMed ID: 18160616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
    Wang WY; Wu YC; Wu CC
    Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet function in clopidogrel-treated patients with acute coronary syndrome.
    Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):335-9. PubMed ID: 17473574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.